Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06539507 · ClinicalTrials.gov registry record · Phase 1

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

A Phase 1 study of Netherton Syndrome, sponsored by BioCryst Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
78
Enrollment target
12
Study locations

NCT06539507 is a Phase 1 study of Netherton Syndrome that is actively recruiting participants, run by BioCryst Pharmaceuticals. The registered enrollment target is 78 participants, above the 16-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (388% higher). The trial reports 12 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06539507, a Phase 1 study of Netherton Syndrome, is actively recruiting participants, sponsored by BioCryst Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
12
Study locations

Study Summary

This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.

Conditions Studied

Netherton Syndrome

Interventions

  • DRUG Placebo
  • DRUG BCX17725

Study Locations (12)

Other

  • Hôpital Saint-Louis - Paris
  • Universitätsklinikum Heidelberg - Heidelberg
  • Maastricht Universitair Medisch Centrum (MUMC+) - Maastricht
  • Erasmus Universitair Medisch Centrum (EMC) - Rotterdam

California

  • Stanford University School of Medicine - Palo Alto
  • Therapeutics Clinical Research - San Diego

Queensland

  • Nucleus Network - Brisbane
  • Veracity Clinical Research - Brisbane

Connecticut

  • Yale Center for Clinical Investigation - New Haven

Illinois

  • Northwestern Dermatology CTU - Chicago

Indiana

  • Dawes Fretzin Clinical Research Group, LLC - Indianapolis

New South Wales

  • Westmead Hospital - Department of Dermatology - Sydney

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2024-09-26
Est. Completion 2026-12
Phase Phase 1

Sponsor

BioCryst Pharmaceuticals

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06539507

The ClinicalTrials.gov registry entry for NCT06539507 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 16-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (388% higher). The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Netherton Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06539507 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Queensland.

Frequently Asked Questions

What is clinical trial NCT06539507 about?

NCT06539507 is a clinical study titled "A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725". This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with ...

What is the current status of trial NCT06539507?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-09-26. Estimated completion is 2026-12.

What conditions does trial NCT06539507 study?

This clinical trial studies the following conditions: Netherton Syndrome.

What interventions are being tested in trial NCT06539507?

The interventions under investigation include: Placebo (DRUG), BCX17725 (DRUG).

Who is sponsoring clinical trial NCT06539507?

This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06539507 being conducted?

This trial has 12 study locations across California, Connecticut, Illinois, Indiana, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Netherton Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Netherton Syndrome

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.